Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35046
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStocco, Amber-
dc.contributor.authorTrawley, Steven-
dc.contributor.authorKong, Yee Wen-
dc.contributor.authorYuan, Cheng Yi-
dc.contributor.authorKiburg, Katerina-
dc.contributor.authorPham, Cecilia-
dc.contributor.authorBrown, Katrin-
dc.contributor.authorPartovi, Andi-
dc.contributor.authorRoem, Kerryn-
dc.contributor.authorHarrison, Natalie-
dc.contributor.authorFourlanos, Spiros-
dc.contributor.authorEkinci, Elif I-
dc.contributor.authorO'Neal, David N-
dc.date2024-
dc.date.accessioned2024-02-07T04:14:24Z-
dc.date.available2024-02-07T04:14:24Z-
dc.date.issued2024-02-01-
dc.identifier.citationDiabetes Research and Clinical Practice 2024-02-01en_US
dc.identifier.issn1872-8227-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35046-
dc.description.abstractUnderstanding the lived experience of using a tubeless insulin pump and how this differs compared to usual care (tubed insulin pump therapy (IPT) vs multiple daily injections (MDI)). Interviews were conducted after 12-weeks of using the Omnipod DASH Insulin Management System (Insulet, Acton, MA) and analysed using thematic analysis. Fifty-eight adults (35 female; mean age 42;SD 13 years; 35 previous MDI) were interviewed. Most (84 %) wanted to continue using the device. Experiences fit two themes: 1. Taking back control of my diabetes: many previous MDI users perceived improved glycaemic control, explained by more "nuanced" control, with some reporting positive effects during exercise and sleep. Many previous MDI and IPT users endorsed positive experiences in concealing or disclosing their diabetes to others. However, some previous MDI users reported negative psychosocial experiences due to feeling continuously "attached" to their diabetes. 2. Barriers and facilitators of device acceptability: both MDI and IPT users cited wearability, alarms and the financial cost impacted their choice to continue device use. IPT users reported positive wearability experiences. The tubeless pump improved diabetes management perceptions for both MDI and tubed pump users. However, participants' prior glucose management affected perceptions of its advantages and disadvantages.en_US
dc.language.isoeng-
dc.subjectInsulin pumpen_US
dc.subjectInterviewsen_US
dc.subjectType 1 diabetesen_US
dc.title"You can hide it if you want to, you can let it be seen if you want to": A qualitative study of the lived experiences of australian adults with type 1 diabetes using the Omnipod DASH® system.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleDiabetes Research and Clinical Practiceen_US
dc.identifier.affiliationCairnmillar Institute, Camberwell, Victoria, Australia.en_US
dc.identifier.affiliationCairnmillar Institute, Camberwell, Victoria, Australia; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationDiabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Victoria, Australia; Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationDiabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationKeylead Health, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationCairnmillar Institute, Camberwell, Victoria, Australia.en_US
dc.identifier.affiliationGeelong Endocrinology and Diabetes, Geelong, Victoria, Australia.en_US
dc.identifier.affiliationDepartment of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Victoria, Australia; Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationDiabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.doi10.1016/j.diabres.2024.111123en_US
dc.type.contentTexten_US
dc.identifier.pubmedid38309532-
dc.description.startpage111123-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.